| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H20ClN3.C11H22O2 |
| Molecular Weight | 512.126 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCC(O)=O.ClC1=CC=C(CN2C(CN3CCCC3)=NC4=CC=CC=C24)C=C1
InChI
InChIKey=WVZNTANSGMGXOL-UHFFFAOYSA-N
InChI=1S/C19H20ClN3.C11H22O2/c20-16-9-7-15(8-10-16)13-23-18-6-2-1-5-17(18)21-19(23)14-22-11-3-4-12-22;1-2-3-4-5-6-7-8-9-10-11(12)13/h1-2,5-10H,3-4,11-14H2;2-10H2,1H3,(H,12,13)
Clemizole is a drug in clinical development for the treatment of hepatitis C virus (HCV) infection. Clemizole is a novel inhibitor of TRPC5 channels. Clemizole is an H1 antagonist. Clemizole, an antihistamine drug that was once widely used for treatment of allergic disease, was recently discovered to be a potent inhibitor (IC50, 24 nM) of the interaction between an HCV protein (NS4B) and HCV RNA. Although clemizole was widely used during the 1950s and 1960s, this was before contemporary regulatory requirements were established for new drug development, and there is very minimal information about its pharmacokinetics and metabolism.
CNS Activity
Originator
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as victim
Tox targets
Sourcing
PubMed
Patents
Sample Use Guides
100 mg Clemizole Hydrochloride Administered Orally Twice a Day for 28 Days
Route of Administration:
Oral
ACTIVE MOIETY
SUBSTANCE RECORD
